encorafenib (Braftovi®) accepted for use within NHSScotland

The SMC has accepted encorafenib in combination with binimetinib for the treatment of adults with unresectable or metastatic melanoma with a BRAF V600 mutation.

SPS commentary:

NICE had also similarly approved encorafenib for this indication.


Scottish Medicines Consortium

Resource links:

NICE TA562 (Feb 2019)